Overview

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)

Status:
Completed
Trial end date:
2020-07-14
Target enrollment:
Participant gender:
Summary
The main reason for this study is to see how the study drug interacts with the body. It will compare different doses of the study drug with a drug already in use. Participants will be adults with liver disease that has affected the brain in the past.
Phase:
Phase 2
Details
Lead Sponsor:
Mallinckrodt
Treatments:
Phenylacetic acid
Rifamycins
Rifaximin